Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gobbini

Showing results (111-120 of 143) with videos related to

Pageof 15
Sort By:
Frontiers in Medicine|May 23, 2022
Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM StudyEnnio Giulio Favalli, Andrea Gobbini, Mauro Bombaci, et al.
Frontiers in Medicine|April 1, 2022
The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM StudyEnnio Giulio Favalli, Andrea Gobbini, Mauro Bombaci, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 13, 2016
How the Human Brain Represents Perceived Dangerousness or "Predacity" of AnimalsAndrew C Connolly, Long Sha, J Swaroop Guntupalli, et al.
Molecular Psychiatry|March 8, 2022
Tricyclic antidepressants target FKBP51 SUMOylation to restore glucocorticoid receptor activityMaia L Budziñski, Clara Sokn, Romina Gobbini, et al.
Clinical Lung Cancer|August 30, 2024
Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line ImmunotherapyC Huet, C Basse, M Knetki-Wroblewska, et al.
Journal of Medicinal Chemistry|July 22, 2008
Novel analogues of istaroxime, a potent inhibitor of Na+,K+-ATPase: synthesis and structure-activity relationshipMauro Gobbini, Silvia Armaroli, Leonardo Banfi, et al.
Nature Communications|March 29, 2025
Type III interferon primes pDCs for TLR7 activation and antagonizes immune suppression mediated by TGF-β and PGE2Candice Sakref, Alexis Saby, Céline Rodriguez, et al.
Clinical Lung Cancer|November 21, 2017
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung CancerElisa Gobbini, Sara Pilotto, Giulia Pasello, et al.
Frontiers in Immunology|August 1, 2022
Anti-Phospholipid Antibodies and Coronavirus Disease 2019: Vaccination Does Not Trigger Early Autoantibody Production in Healthcare WorkersMaria Orietta Borghi, Mauro Bombaci, Caterina Bodio, et al.
Science Immunology|April 19, 2020
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancerMargaux Hubert, Elisa Gobbini, Coline Couillault, et al.
Pageof 15

Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
Frontiers in Medicine|May 23, 2022
Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM StudyEnnio Giulio Favalli, Andrea Gobbini, Mauro Bombaci, et al.
Frontiers in Medicine|April 1, 2022
The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM StudyEnnio Giulio Favalli, Andrea Gobbini, Mauro Bombaci, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 13, 2016
How the Human Brain Represents Perceived Dangerousness or "Predacity" of AnimalsAndrew C Connolly, Long Sha, J Swaroop Guntupalli, et al.
Molecular Psychiatry|March 8, 2022
Tricyclic antidepressants target FKBP51 SUMOylation to restore glucocorticoid receptor activityMaia L Budziñski, Clara Sokn, Romina Gobbini, et al.
Clinical Lung Cancer|August 30, 2024
Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line ImmunotherapyC Huet, C Basse, M Knetki-Wroblewska, et al.
Journal of Medicinal Chemistry|July 22, 2008
Novel analogues of istaroxime, a potent inhibitor of Na+,K+-ATPase: synthesis and structure-activity relationshipMauro Gobbini, Silvia Armaroli, Leonardo Banfi, et al.
Nature Communications|March 29, 2025
Type III interferon primes pDCs for TLR7 activation and antagonizes immune suppression mediated by TGF-β and PGE2Candice Sakref, Alexis Saby, Céline Rodriguez, et al.
Clinical Lung Cancer|November 21, 2017
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung CancerElisa Gobbini, Sara Pilotto, Giulia Pasello, et al.
Frontiers in Immunology|August 1, 2022
Anti-Phospholipid Antibodies and Coronavirus Disease 2019: Vaccination Does Not Trigger Early Autoantibody Production in Healthcare WorkersMaria Orietta Borghi, Mauro Bombaci, Caterina Bodio, et al.
Science Immunology|April 19, 2020
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancerMargaux Hubert, Elisa Gobbini, Coline Couillault, et al.
Pageof 15